Upgrade to SI Premium - Free Trial

AstraZeneca invests $2B in Summit Therapeutics preferred shares

September 28, 2026 5:33 PM
AstraZeneca (NYSE: AZN) has agreed to invest $2.0 billion in Summit Therapeutics (NASDAQ: SMMT) through the purchase of convertible preferred ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Trader Talk

Next Articles